Gilead Sciences Inc
said on Tuesday it was in discussions with chemical and drug
manufacturers to produce its antiviral drug remdesivir for Europe, Asia
and the developing world through at least 2022.
The drugmaker last week received the U.S. Food and Drug
Administration’s emergency use authorisation for using remdesivir as a
treatment against COVID-19, the respiratory illness caused by the new
coronavirus.
Gilead also said on Tuesday it was negotiating long-term voluntary
licenses with several generic drugmakers in India and Pakistan to
produce remdesivir for developing countries.
https://www.marketscreener.com/GILEAD-SCIENCES-4876/news/Gilead-Sciences-in-talks-to-expand-global-supply-of-COVID-19-drug-remdesivir-30545153/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.